TPH1 and diabetes mellitus: Systemic tryptophan hydroxylase 1 inhibitors and a peripheral tryptophan hydroxylase 1 inhibitor (LP-533401) have been patented for use in treating diabetes and obesity (Kolodziejczak et al., 2015; Abg Abd Wahab et al., 2019).